Technical Report Neurosurgery Physical Medicine & Rehabilitation I am not a medical professional
30-day readmission after high-flow nasal oxygen in children with asthma: A randomised controlled trial

30-day readmission after high-flow nasal oxygen in children with asthma: A randomised controlled trial

Authors

Lucas Ibrahim

Lucas Ibrahim

Toronto General Hospital, Samoa

Corresponding
Omar Dubois

Omar Dubois

Aga Khan University Hospital, Uganda

Mariam Yilmaz

Mariam Yilmaz

Singapore General Hospital, Virgin Islands (British)

Published

April 23, 2026

Paper ID

PAP-000194

Status

Published

DOI

10.65712/tmj.test000452

30-day readmission after high-flow nasal oxygen in children with asthma: A randomised controlled trial

Advance Services

Create Content

Video • Presentation • Poster

From $97.00 per format

Abstract

Background: Earlier studies of high-flow nasal oxygen were small or single-centre. Methods: We conducted a randomised controlled trial across 5 centres between 2018 and 2024. Results: Effects were consistent across prespecified subgroups. 1315 participants were included (median age 72 years). Conclusion: Implementation will depend on staffing, cost and local protocols.

Introduction

Practice around high-flow nasal oxygen varies widely between centres. Earlier studies of high-flow nasal oxygen were small or single-centre. 30-day readmission remains a leading cause of avoidable harm among children with asthma.

Earlier studies of high-flow nasal oxygen were small or single-centre. The cost of 30-day readmission to health systems is substantial.

Guidelines make only a weak recommendation on high-flow nasal oxygen. 30-day readmission remains a leading cause of avoidable harm among children with asthma.

Earlier studies of high-flow nasal oxygen were small or single-centre. The cost of 30-day readmission to health systems is substantial.

Discussion

These findings suggest that high-flow nasal oxygen is associated with better 30-day readmission in children with asthma. Residual confounding cannot be excluded.

Residual confounding cannot be excluded. Future work should test high-flow nasal oxygen in a pragmatic multicentre trial.

Conclusions

High-flow nasal oxygen should be considered for children with asthma to improve 30-day readmission.

References

1. Novak U, Ahmed E, et al. Early mobilisation and falls. JAMA. 2019;86(7):539-1634.

2. Dubois U, Tanaka Z, et al. Early mobilisation and in-hospital mortality. BMJ. 2008;215(4):133-1197.

3. Rahman X, Costa M, et al. Point-of-care ultrasound and glycaemic control. Crit Care Med. 2008;321(10):648-902.

4. Yilmaz H, Nasser V, et al. Delayed cord clamping and glycaemic control. Eur Heart J. 2014;138(8):106-1434.

5. Moreau G, Patel I, et al. Continuous glucose monitoring and health-related quality of life. Crit Care Med. 2023;23(7):756-1095.

6. Zhang V, Larsen E, et al. Vitamin D supplementation and medication adherence. JAMA. 2020;211(2):808-1377.

7. Silva O, Silva U, et al. Pharmacist-led medication review and falls. N Engl J Med. 2016;148(9):309-1054.

8. Mueller R, Schmidt R, et al. Vitamin D supplementation and surgical site infection. BMJ. 2011;151(11):890-1798.

9. Kowalski B, Rossi J, et al. High-flow nasal oxygen and chronic pain scores. N Engl J Med. 2008;124(9):3-992.

Appendices

Ethics approval: IRB-3272.

Materials and Methods

Eligible participants were children with asthma. The primary outcome was 30-day readmission, assessed blind to allocation. Analyses were adjusted for age, sex and baseline severity. We conducted a randomised controlled trial across 11 centres between 2019 and 2023.

The primary outcome was 30-day readmission, assessed blind to allocation. Missing data were handled with multiple imputation.

Eligible participants were children with asthma. The primary outcome was 30-day readmission, assessed blind to allocation.

Results

Effects were consistent across prespecified subgroups. The adjusted odds ratio was 0.82 (95% CI 0.27 to 0.80).

The adjusted odds ratio was 0.60 (95% CI 0.31 to 0.95). 4084 participants were included (median age 28 years). 3596 participants were included (median age 44 years).

GroupnEventsRate %OR
Control6607730.60.93
Intervention24258.70.51
Intervention371068.40.60
TABLE 1: Primary outcome by group
Values are n (%) unless stated otherwise.
Figure 1
FIGURE 1: Distribution of 30-day readmission
Shown for children with asthma; error bars are 95% confidence intervals.

Effects were consistent across prespecified subgroups. Serious adverse events were rare and similar between groups. The adjusted odds ratio was 0.81 (95% CI 0.31 to 0.75).